

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of: Chang

Art Unit: 1642

Application No. 09/826,115

Filed: April 4, 2001

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Not yet known

Date: April 11, 2003

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 11, 2003, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

Tanya M. Harding, Ph.D.
Attorney for Applicant

TRANSMITTAL LETTER

COPY

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and copies of (20) references cited thereon
- ☒ The Director is hereby authorized to charge any fees that may be required to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Not yet known

Date: April 11, 2003

Art Unit: 1642

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 11, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Tanya M. Harding, Ph.D.
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this Information Disclosure Statement, please see the attached transmittal letter for deposit account authority.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64907
Application Number	09/701,536
Filing Date	November 19, 2000
First Named Inventor	Chang
Art Unit	1642
Examiner Name	Not yet known

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		4,810,492	March 7, 1989	Fujita <i>et al.</i>
		5,021,347	June 4, 1991	Yasui <i>et al.</i>
		5,229,293	July 20, 1993	Matsuura <i>et al.</i>
		5,494,671	Feb. 27, 1996	Lai <i>et al.</i>
		5,514,375	May 7, 1996	Paoletti <i>et al.</i>
		6,074,865	June 13, 2000	Kelly <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 92/02548 (French w/English abstract)	May 20, 1991	WIPO
		WO 93/06214	April 1, 1993	WIPO
		WO 02/072036	Sept. 19, 2002	WIPO
		WO 02/083903	Oct. 24, 2002	WIPO
		JP 89025725 (English Abstract only)	May 1989	JAPAN
		JP 53133627 (English Abstract only)	November 1978	JAPAN
		JP 63004895 (English Abstract only)	1963	JAPAN
		JP 63105682 (English Abstract only)	May 10, 1988	JAPAN
		JP 65000611 (English Abstract only)	1965	JAPAN

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64908
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1642
Examiner Name	Not yet known

		Monath, "Flaviviruses," <i>Virology</i> (R.N. Fields, ed.) 763-814, 1990
--	--	--

		Pincus <i>et al.</i> , "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," <i>Virology</i> 187:290-297, 1992
--	--	---

		Ramelow <i>et al.</i> , "Detection of tick-borne encephalitis virus RNA in ticks (<i>Ixodes ricinus</i>) by the polymerase chain reaction," <i>J. Virological Methods</i> 45:115-119, 1993
--	--	--

		Schalich <i>et al.</i> , "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," <i>J. Virol.</i> 70(7):4549-4557, 1996
--	--	---

		Smithburn <i>et al.</i> , "A neurotropic virus isolated from the blood of a native of uganda," <i>Am. J. Trop. Med.</i> 20: 471-492, 1940
--	--	---

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

CLIENT/MATTER NO. 6395-64908 ATTY/SEC TMH:jlb

INVENTOR(S): Chang

APP. NO. 09/826,115

FILING DATE 4-4-01

The following, due 4-11-03, mailed 4-11-03

by First Class Mail, was received in the U.S. PTO on the date stamped hereon:

<input type="checkbox"/> Amendment	<input type="checkbox"/> Marked Up Claims/Spec.	<input type="checkbox"/> After Final Rejection
<input type="checkbox"/> Extension of Time/Extension Fee for <u> </u> Months		
<input type="checkbox"/> Notice to File Missing Parts - Date <u> </u>		<input type="checkbox"/> Ltr to Draftsperson
<input type="checkbox"/> Notice to File Corrected App. Papers - Date <u> </u>		<input type="checkbox"/> Notice-Allowability
<input type="checkbox"/> Comb. Dec./POA <input type="checkbox"/> Sht(s) Drawings <u> </u>		<input type="checkbox"/> Sht(s) Drawings
<input type="checkbox"/> Issue Fee Transmittal (Form PTOL-85b)		<input type="checkbox"/> Sequence Listing <u> </u> pages
<input type="checkbox"/> Supp. Dec.	<input type="checkbox"/> Issue/Adv. Order fees	<input type="checkbox"/> Stmt in Comp. <u> </u> Disk
<input checked="" type="checkbox"/> IDS	<input checked="" type="checkbox"/> Form PTO-1449/Ref. <u>(20)</u>	<input type="checkbox"/> Petition
Assignment to: <u> </u>		<input type="checkbox"/> Recordal Sheet
<input checked="" type="checkbox"/> Transmittal Ltr. + <input checked="" type="checkbox"/> 1-2 copyties		<input type="checkbox"/> Request for Corrected Filing Receipt
Check No. <u> </u> for \$ <u> </u>		<input checked="" type="checkbox"/> Deposit Acct. 02-4550 Authority

CLIENT/MATTER NO. 6395-64908

INVENTOR(S): Chang

APP. NO. 09/826,115

ATTY/SEC TMH:jlb

The following, due 4-4-01

FILING DATE 4-4-01

by First Class Mail, was received in the U.S. PTO on the date stamped hereon:

<input type="checkbox"/> Amendment	<input type="checkbox"/> Marked Up Claims/Spec.	<input type="checkbox"/> After Final Rejection
<input type="checkbox"/> Extension of Time/Extension Fee for <u> </u> Months		
<input type="checkbox"/> Notice to File Missing Parts - Date <u> </u>		<input type="checkbox"/> Ltr to Draftsperson
<input type="checkbox"/> Notice to File Corrected App. Papers - Date <u> </u>		<input type="checkbox"/> Notice-Allowability
<input type="checkbox"/> Comb. Dec./POA <input type="checkbox"/> Sht(s) Drawings <u> </u>		<input type="checkbox"/> Sht(s) Drawings
<input type="checkbox"/> Issue Fee Transmittal (Form PTOL-85b)		<input type="checkbox"/> Sequence Listing <u> </u> pages
<input checked="" type="checkbox"/> Supp. Dec.	<input type="checkbox"/> Issue/Adv. Order fees	<input type="checkbox"/> Stmt in Comp. <u> </u> Disk
<input checked="" type="checkbox"/> IDS	<input checked="" type="checkbox"/> Form PTO-1449/Ref. <u>(20)</u>	<input type="checkbox"/> Petition
Assignment to: <u> </u>		<input type="checkbox"/> Recordal Sheet
<input checked="" type="checkbox"/> Transmittal Ltr. + <input checked="" type="checkbox"/> 1-2 copyties		<input type="checkbox"/> Request for Corrected Filing Receipt
Check No. <u> </u> for \$ <u> </u>		<input checked="" type="checkbox"/> Deposit Acct. 02-4550 Authority

EXHIBIT

B



TMH: 06/28/04 6395-64908-01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

Confirmation No. 4134

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1648

Attorney Reference No. 6395-64908-01

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed June 28, 2004

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed are four English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicant received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

07/02/2004 MBERHE 00000071 09826115

02 FC:1806

180.00 0P

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391; Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64908-01
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,258,788	07/10/2001	Schmaljohn

OTHER REFERENCES

		Chang <i>et al.</i> , "Recent advancement in flavivirus vaccine development" <i>Expert Rev. Vaccines</i> 3(2):199-220, 2004
		Guirakhoo <i>et al.</i> , "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates" <i>J. Virol.</i> 74(12):5477-5485, 2000
		Simmons <i>et al.</i> , "Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine" <i>Am. J. Trop. Med. Hyg.</i> 65(2):159-161, 2001

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.